Ardelyx Faces Securities Class Action After Revenue Guidance Cuts

The litigation follows an August 6, 2026, announcement in which Ardelyx reduced its full-year revenue guidance for IBSRELA and withdrew long-term projections for XPHOZAH. Company management cited increased payer utilization-management hurdles that hampered patient access and slowed new-patient acquisition, alongside vague concerns regarding evolving market dynamics. Following the disclosure, the company's stock price dropped $0.87 per share—a 17.86% decline—closing at $4.00 on August 7, 2026.

Investors who purchased or acquired Ardelyx securities during the specified class period have until November 16, 2026, to petition the court for appointment as lead plaintiff. Those interested in participating can contact Danielle Peyton at Pomerantz LLP for further details on the complaint.